Al-Momany B, Hammad H, Ahram M (2021) Dihydrotestosterone induces chemo-resistance of triple-negative breast MDA-MB-231 cancer cells towards doxorubicin independent of ABCG2 and miR-328-3p. Curr Mol Pharmacol 14(5):860–870

Article  CAS  PubMed  Google Scholar 

Alshaer W et al (2019) Downregulation of STAT3, β-catenin, and notch-1 by single and combinations of siRNA treatment enhance chemosensitivity of wild type and doxorubicin resistant MCF7 breast cancer cells to doxorubicin. Int J Mol Sci 20(15):3696

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ashrafizadeh M et al (2022) Exosomes as promising nanostructures in diabetes mellitus: from insulin sensitivity to ameliorating diabetic complications. Int J Nanomed 17:1229

Article  CAS  Google Scholar 

Ashrafizadeh M et al (2023) A bioinformatics analysis, pre-clinical and clinical conception of autophagy in pancreatic cancer: complexity and simplicity in crosstalk. Pharmacol Res 194:106822

Article  CAS  PubMed  Google Scholar 

Atteia HH et al (2021) Thymoquinone upregulates miR-125a-5p, attenuates STAT3 activation, and potentiates doxorubicin antitumor activity in murine solid Ehrlich carcinoma. J Biochem Mol Toxicol 35(12):e22924

Article  CAS  PubMed  Google Scholar 

Ayyildiz A et al (2021) Co-administration of apigenin with doxorubicin enhances anti-migration and antiproliferative effects via PI3K/PTEN/AKT pathway in prostate cancer cells. Exp Oncol 43(2):125–134

Article  CAS  PubMed  Google Scholar 

Baixauli F, López-Otín C, Mittelbrunn M (2014) Exosomes and autophagy: coordinated mechanisms for the maintenance of cellular fitness. Front Immunol 5:403

Article  PubMed  PubMed Central  Google Scholar 

Bao L et al (2012) Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 180(6):2490–2503

Article  CAS  PubMed  PubMed Central  Google Scholar 

Batist G et al (2002) Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin Pharmacother 3(12):1739–1751

Article  CAS  PubMed  Google Scholar 

Buchholz TA et al (2002) Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 8(6):461–468

Article  PubMed  Google Scholar 

Cao Y et al (2021) LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p/Nova1 axis. Mol Cell Biochem 476(1):279–292

Article  CAS  PubMed  Google Scholar 

Carvalho C et al (2009) Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16(25):3267–3285

Article  CAS  PubMed  Google Scholar 

Chang H-I, Yeh M-K (2012) Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomed 7:49

CAS  Google Scholar 

Chen Y et al (2017) miR-27b-3p suppresses cell proliferation, migration and invasion by targeting LIMK1 in colorectal cancer. Int J Clin Exp Pathol 10(9):9251–9261

PubMed  PubMed Central  Google Scholar 

Chen D et al (2018a) miR-27b-3p inhibits proliferation and potentially reverses multi-chemoresistance by targeting CBLB/GRB2 in breast cancer cells. Cell Death Dis 9(2):188

Article  PubMed  PubMed Central  Google Scholar 

Chen J et al (2018b) miR-21-5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3. Int J Mol Med 41(4):1855–1866

CAS  PubMed  PubMed Central  Google Scholar 

Chen M et al (2018c) miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression. EBioMedicine 35:142–154

Article  PubMed  PubMed Central  Google Scholar 

Chen W et al (2019) Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin. Biomaterials 192:590–600

Article  CAS  PubMed  Google Scholar 

Chen S et al (2021a) MiR-199b-5p promotes gastric cancer progression by regulating HHIP expression. Front Oncol 11:728393

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Q et al (2021b) MiR-873-5p targets THUMPD1 to inhibit gastric cancer cell behavior and chemoresistance. J Gastrointest Oncol 12(5):2061–2072

Article  PubMed  PubMed Central  Google Scholar 

Dai H et al (2019) MicroRNA-222 promotes drug resistance to doxorubicin in breast cancer via regulation of miR-222/bim pathway. Biosci Rep 39(7):BSR2019

Article  Google Scholar 

Dai G et al (2021) Expression of miR-187 and miR-509-3p in serum of primary hepatocellular carcinoma patients and its evaluation of prognosis. J BUON 26(4):1340–1345

PubMed  Google Scholar 

Deng Z et al (2017) Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis. Oncogene 36(5):639–651

Article  CAS  PubMed  Google Scholar 

Ding J et al (2018) MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7. Acta Biochim Biophys Sin (shanghai) 50(6):597–604

Article  CAS  PubMed  Google Scholar 

Dou D et al (2020) CircUBE2D2 (hsa_circ_0005728) promotes cell proliferation, metastasis and chemoresistance in triple-negative breast cancer by regulating miR-512-3p/CDCA3 axis. Cancer Cell Int 20:454

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doublier S et al (2012) HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer 12:4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Du F et al (2019) miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4. Cell Death Dis 10(12):922

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fan YP et al (2017) MiR-375 and doxorubicin co-delivered by liposomes for combination therapy of hepatocellular carcinoma. Mol Ther Nucleic Acids 7:181–189

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fang J et al (2020) A nanomicelle with miR-34a and doxorubicin reverses the drug resistance of cisplatin in esophageal carcinoma cells by inhibiting SIRT1 signal pathway. Transl Cancer Res 9(7):4131–4140

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farago AF et al (2019) ATLANTIS: a phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. Future Oncol 15(3):231–239

Article  CAS  PubMed  Google Scholar 

Gajda E et al (2020) Combinatory treatment with miR-7-5p and drug-loaded cubosomes effectively impairs cancer cells. Int J Mol Sci 21(14):5039

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao AM, Zhang XY, Ke ZP (2017) Apigenin sensitizes BEL-7402/ADM cells to doxorubicin through inhibiting miR-101/Nrf2 pathway. Oncotarget 8(47):82085–82091

Article  PubMed  PubMed Central  Google Scholar 

Gao AM et al (2018) Apigenin sensitizes hepatocellular carcinoma cells to doxorubic through regulating miR-520b/ATG7 axis. Chem Biol Interact 280:45–50

Article  CAS  PubMed  Google Scholar 

Gao M et al (2020a) Orphan nuclear receptor RORγ confers doxorubicin resistance in prostate cancer. Cell Biol Int 44(10):2170–2176

Article  CAS  PubMed  Google Scholar 

Gao H et al (2020b) Exosomal transfer of macrophage-derived miR-223 confers doxorubicin resistance in gastric cancer. Onco Targets Ther 13:12169–12179

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao J et al (2021a) Curcumol increases the sensitivity of colon cancer to 5-FU by regulating Wnt/β-catenin signaling. Transl Cancer Res 10(5):2437–2450

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao X, Jiang Y, Li Y (2021b) Inhibitory effect of miR-140-5p on doxorubicin resistance of hepatocellular carcinoma. Exp Ther Med 21(5):507

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garg M et al (2020) The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy. Med Res Rev 41:1291